Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice (original) (raw)

Abstract

The role of prolactin in human breast cancer has been controversial. However, it is now apparent that human mammary epithelial cells can synthesize prolactin endogenously, permitting autocrine/ paracrine actions within the mammary gland that are independent of pituitary prolactin. To model this local mammary production of prolactin (PRL), we have generated mice that overexpress prolactin within mammary epithelial cells under the control of a hormonally nonresponsive promoter, neurelated lipocalin (NRL). In each of the two examined NRL-PRL transgenic mouse lineages, female virgin mice display mammary developmental abnormalities, mammary intraepithelial neoplasias, and invasive neoplasms. Prolactin increases proliferation in morphologically normal alveoli and ducts, as well as in lesions. The tumors are of varied histotype, but papillary adenocarcinomas and adenosquamous neoplasms predominate. Neoplasms can be separated into two populations: one is estrogen receptor alpha (ERα) positive (greater than 15% of the cells stain for ERα), and the other is ERα−(<3%). ERα expression does not correlate with tumor histotype, or proliferative or apoptotic indices. These studies provide a mouse model of hormonally dependent breast cancer, and, perhaps most strikingly, a model in which some neoplasms retain ERα, as occurs in the human disease.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (63)

  1. Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Oncogene 2002;21:198-206. [PubMed: 11803463]
  2. Amundadottir LT, Merlino G, Dickson RB. Breast Cancer Res Treat 1996;39:119-135. [PubMed: 8738611]
  3. Beck MT, Peirce SK, Chen WY. Oncogene 2002;21:5047-5055. [PubMed: 12140755] Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Endocr Rev 1996;17:639-669. [PubMed: 8969972]
  4. Bera TK, Hwang S, Swanson SM, Guzman RC, Edery M, Nandi S. Mol Cell Biochem 1994;132:145- 149. [PubMed: 7969097]
  5. Boot LM, Muhlbock O, Ropcke G. Gen Comp Endocrinol 1962;2:601-603.
  6. Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD. Proc Natl Acad Sci USA 1985;82:4438- 4442. [PubMed: 3892534]
  7. Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, Kelly PA, Ormandy CJ. Dev Biol 1999;210:96-106. [PubMed: 10364430]
  8. Brockman JL, Schroeder MD, Schuler LA. Mol Endocrinol 2002;16:774-784. [PubMed: 11923474]
  9. Camarillo IG, Thordarson G, Moffat JG, Van Horn KM, Binart N, Kelly PA, Talamantes F. J Endocrinol 2001;171:85-95. [PubMed: 11572793]
  10. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. Oncogene 2000;19:968-988. [PubMed: 10713680]
  11. Christov K, Swanson SM, Guzman RC, Thordarson G, Jin E, Talamantes F, Nandi S. Carcinogenesis 1993;14:2019-2025. [PubMed: 8222048]
  12. Christov KT, Guzman RC, Swanson SM, Thordarson G, Talamantes F, Nandi S. Carcinogenesis 1996;17:1741-1746. [PubMed: 8761435]
  13. Clarke RB, Howell A, Potten CS, Anderson E. Cancer Res 1997;57:4987-4991. [PubMed: 9371488]
  14. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. Endocr Rev 2003;24:1-27. [PubMed: 12588805]
  15. Cooke NE, Baxter JD. Nature 1982;297:603-606. [PubMed: 6283362]
  16. DeOme KB, Faulkin LJ, Bern HA, Blair PB. Cancer Res 1959;19:515-520. [PubMed: 13663040] Edery M, Imagawa W, Larson L, Nandi S. Endocrinology 1985;116:105-112. [PubMed: 2981060]
  17. Evan GI, Vousden KH. Nature 2001;411:342-348. [PubMed: 11357141]
  18. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA. Mol Cell Endocrinol 1999;151:79-87. [PubMed: 10411322]
  19. Gout PW, Beer CT, Noble RL. Cancer Res 1980;40:2433-2436. [PubMed: 6992985]
  20. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C. Oncogene 2000;19:1020-1027. [PubMed: 10713685]
  21. Grimm SL, Seagroves TN, Kabotyanski EB, Hovey RC, Vonderhaar BK, Lydon JP, Miyoshi K, Hennighausen L, Ormandy CJ, Lee AV, Stull MA, Wood TL, Rosen JM. Mol Endocrinol 2002;16:2675-2691. [PubMed: 12456789]
  22. Grippo PJ, Sandgren EP. Am J Pathol 2000;157:805-813. [PubMed: 10980120]
  23. Hankinson SE, Willett WC, Michaud S, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. J Natl Cancer Inst 1999;91:629-634. [PubMed: 10203283]
  24. Horseman ND, Zhao WZ, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. EMBO J 1997;16:6926-6935. [PubMed: 9384572]
  25. Hovey RC, Trott JF, Ginsburg E, Goldhar A, Sasaki MM, Fountain SJ, Sundararajan K, Vonderhaar BK. Dev Dyn 2001;222:192-205. [PubMed: 11668597]
  26. Hu Z-Z, Meng J, Dufau ML. J Biol Chem 2001;276:41086-41094. [PubMed: 11518703]
  27. Humphreys RC, Hennighausen L. Cell Growth Differ 1999;10:685-694. [PubMed: 10547072]
  28. Huseby RA, Soares MJ, Talamantes F. Endocrinology 1985;116:1440-1448. [PubMed: 3971922]
  29. Imagawa W, Pedchenko VK, Helber J, Zhang HZ. J Steroid Biochem Mol Biol 2002;80:213-230. [PubMed: 11897505]
  30. Jamerson MH, Johnson MD, Dickson RB. Oncogene 2000;19:1065-1071. [PubMed: 10713691]
  31. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Toxicol Pathol 1996;24:710-716. [PubMed: 8994298]
  32. Medina D. Biochim Biophys Acta 2002;1603:1. [PubMed: 12242106]
  33. Mertani HC, Garcia-Caballero T, Lambert A, Gérard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G. Int J Cancer 1998;79:202-211. [PubMed: 9583737]
  34. Muldoon TG. Endocrinology 1987;121:141-149. [PubMed: 3595517]
  35. O'Neal KD, Yu-Lee L. J Biol Chem 1994;269:26076-26082. [PubMed: 7929319]
  36. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA. Genes Dev 1997a;11:167-178. [PubMed: 9009200]
  37. Ormandy CJ, Hall RE, Manning DL, Robertson JFR, Blamey RW, Kelly PA, Nicholson RI, Sutherland RL. J Clin Endocrinol Metab 1997b;82:3692-3699. [PubMed: 9360527]
  38. Otten AD, Sanders MM, McKnight GS. Mol Endocrinol 1988;2:143-147. [PubMed: 2840570]
  39. Qin W, Golovkina TV, Peng T, Nepomnaschy I, Buggiano V, Piazzon I, Ross SR. J Virol 1999;73:368- 376. [PubMed: 9847341]
  40. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Endocrinology 1997;138:5555- 5560. [PubMed: 9389544]
  41. Rose-Hellekant TA, Gilchrist K, Sandgren EP. Am J Pathol 2002;161:1439-1447. [PubMed: 12368216]
  42. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD. Am J Pathol 2002;161:1087-1097. [PubMed: 12213737]
  43. Russo J, Ao X, Grill C, Russo IH. Breast Cancer Res Treat 1999;53:217-227. [PubMed: 10369068]
  44. Schroeder MD, Rose-Hellekant T, Sandgren EPand Schuler LA. Mol Cell Endocrinol 2001;175:173- 183. [PubMed: 11325527]
  45. Schroeder MD, Symowicz J, Schuler LA. Mol Endocrinol 2002;16:45-57. [PubMed: 11773438]
  46. Schwertfeger KL, Richert MM, Anderson SM. Mol Endocrinol 2001;15:867-881. [PubMed: 11376107]
  47. Shafie S, Brooks SC. Cancer Res 1977;37:792-799. [PubMed: 189915]
  48. Shiu RPC, Elsholtz HP, Tanaka T, Friesen HG, Gout PW, Beer CT, Noble RL. Endocrinology 1983;113:159-165. [PubMed: 6305632]
  49. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP. Am J Pathol 1999;155:1811-1815. [PubMed: 10595909]
  50. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S. J Steroid Biochem Mol Biol 2002;80:137-148. [PubMed: 11897499]
  51. Silberstein GB. Breast Cancer Res 2001;3:218-223. [PubMed: 11434872] Stoesz SPand Gould MN. Oncogene 1995;11:2233-2241. [PubMed: 8570173]
  52. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA. J Clin Endocrinol Metab 1998;83:667-674. [PubMed: 9467590]
  53. Tseng YH, Kessler MA, Schuler LA. Mol Cell Endocrinol 1997;128:117-127. [PubMed: 9140083]
  54. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Oncogene 2000;19:1077-1084. [PubMed: 10713693]
  55. Vonderhaar, BK. Endocrine Oncology. Ethier, SP., editor. Humana Press; Totowa, NJ: 2000. p. 101-120.
  56. Welsch CW, Nagasawa H. Cancer Res 1977;37:951-963. [PubMed: 191183]
  57. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OGPand Törnell J. J Clin Invest 1997;100:2744-2751. [PubMed: 9389738]
  58. Wennbo H, Törnell J. Oncogene 2000;19:1072-1076. [PubMed: 10713692]
  59. Wiseman BS, Werb Z. Science 2002;296:1046-1049. [PubMed: 12004111]
  60. Yarus S, Hadsell D, Rosen JM. Genet Eng 1996;18:57-81.
  61. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE. Cancer Res 2000;60:6901-6910. [PubMed: 11156389]
  62. Yu-Lee L. Mol Cell Endocrinol 1990;68:21-28. [PubMed: 2406173]
  63. Zeps N, Bentel JM, Papadimitriou JM, D'Antuono MF, Dawkins HJ. Differentiation 1998;62:221-226. [PubMed: 9566307]